Development of Machine Learning Algorithms for the Prediction of Financial Toxicity in Localized Breast Cancer Following Surgical Treatment
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PURPOSE: Financial burden caused by cancer treatment is associated with material loss, distress, and poorer outcomes. Financial resources exist to support patients but identification of need is difficult. We sought to develop and test a tool to accurately predict an individual's risk of financial toxicity based on clinical, demographic, and patient-reported data prior to initiation of breast cancer treatment. PATIENTS AND METHODS: We surveyed 611 patients undergoing breast cancer therapy at MD Anderson Cancer Center. We collected data using the validated COmprehensive Score for financial Toxicity (COST) patient-reported outcome measure alongside other financial indicators (credit score, income, and insurance status). We also collected clinical and perioperative data. We trained and tested an ensemble of machine learning (ML) algorithms (neural network, regularized linear model, support vector machines, and a classification tree) to predict financial toxicity. Data were randomly partitioned into training and test samples (2:1 ratio). Predictive performance was assessed using area-under-the-receiver-operating-characteristics-curve (AUROC), accuracy, sensitivity, and specificity. RESULTS: In our test sample (N = 203), 48 of 203 women (23.6%) reported significant financial burden. The algorithm ensemble performed well to predict financial burden with an AUROC of 0.85, accuracy of 0.82, sensitivity of 0.85, and specificity of 0.81. Key clinical predictors of financial burden from the linear model were neoadjuvant therapy (β regularized, .11) and autologous, rather than implant-based, reconstruction (β regularized, .06). Notably, radiation and clinical tumor stage had no effect on financial burden. CONCLUSION: ML models accurately predicted financial toxicity related to breast cancer treatment. These predictions may inform decision making and care planning to avoid financial distress during cancer treatment or enable targeted financial support. Further research is warranted to validate this tool and assess applicability for other types of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies
Wolff, R. F., Moons, K. G. M., Riley, R. D., Whiting, P. F., Westwood, M., Collins, G. S., Reitsma, J. B., Kleijnen, J., Mallett, S., & for the PROBAST Group† (2019) · Annals of Internal Medicine · doi:10.7326/m18-1376 · Cited by 2,984 · cited 1×
“We used the Prediction Model Study Risk of Bias Assessment Tool (PROBAST) to ensure high accuracy when these models were used elsewhere.(25) We normalized the range of all values using feature scaling.”
Artificial intelligence in healthcare
Yu, K.-H., Beam, A. L., & Kohane, I. S. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0305-z · Cited by 2,817
STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration
Cohen, J. F., Korevaar, D. A., Altman, D. G., Bruns, D. E., Gatsonis, C. A., Hooft, L., Irwig, L., Levine, D., Reitsma, J. B., de Vet, H. C. W., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012799 · Cited by 2,570
Ramsey, S., Blough, D., Kirchhoff, A., Kreizenbeck, K., Fedorenko, C., Snell, K., Newcomb, P., Hollingworth, W., & Overstreet, K. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1263 · Cited by 699
Patient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Cited by
Artificial Intelligence Advancements in Oncology: A Review of Current Trends and Future Directions
Huhulea, E. N., Huang, L., Eng, S., Sumawi, B., Huang, A., Aifuwa, E., Hirani, R., Tiwari, R. K., & Etienne, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040951 · Cited by 74
Pfob, A., Sidey-Gibbons, C., Barr, R. G., Duda, V., Alwafai, Z., Balleyguier, C., Clevert, D.-A., Fastner, S., Gomez, C., Goncalo, M., et al. (2022) · European Radiology · doi:10.1007/s00330-021-08519-z · Cited by 29
“…Analyzing contextualizing patient information for complex risk assessments by AI-based algorithms has yielded promising results in other fields [13–15] Thus, the absent integration of contextualizing clinical and demographic information and of different imaging modalities into AI-based,…”
BackgroundMethodSelf-citationPfob, A., Sidey-Gibbons, C., Barr, R. G., Duda, V., Alwafai, Z., Balleyguier, C., Clevert, D.-A., Fastner, S., Gomez, C., Goncalo, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.09.018 · Cited by 27
Self-citation
Metadata
- Authors
- Sidey-Gibbons, C., Pfob, A., Asaad, M., Boukovalas, S., Lin, Y.-L., Selber, J. C., Butler, C. E., & Offodile, A. C.
- Venue
- JCO Clinical Cancer Informatics
- Published
- 2021-12
- Volume
- 5
- Issue
- 5
- Pages
- 338-347
- ISSN
- 2473-4276 (ISSN-L)
- OpenAlex
- W3138697839
- Cited by
- 60
- References
- 5
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Machine Learning Algorithms for the Prediction of Financial Toxicity in Localized Breast Cancer Following Surgical Treatment. https://app.cochat.ai/papers/10.1200/cci.20.00088
- The paper
- Sidey-Gibbons, C., Pfob, A., Asaad, M., Boukovalas, S., Lin, Y.-L., Selber, J. C., Butler, C. E., & Offodile, A. C. (2021). Development of Machine Learning Algorithms for the Prediction of Financial Toxicity in Localized Breast Cancer Following Surgical Treatment. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.20.00088
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.